medigraphic.com

2018, Number 18

<< Back

waxapa 2018; 10 (18)

Risk factors, comorbidity and treatment of psoriasis

Goribar EJ, Goribar TB, Trejo FJ, Goribar TC, Flores PL

Language: Spanish
References: 28
Page: 31-35
PDF size: 101.92 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Sociedad Latinoamericana. Consenso Latinoamericano de Psoriasis–Guías de Tratamiento. Actualización. 2009:10-33.

  2. Coimbra, Susana, et al. Psoriasis: Epidemiology, Clinical and Histological Features, Triggering Factors, Assessment of Severity and Psychosocial Aspects. En Psoriasis-A Systemic Disease. INTECH Open Access Publisher.2012.

  3. Guerra, M.A, et al. Consenso mexicano para el manejo de terapia biológica en psoriasis. Rev Cent Dermatol Pascua.2004: 172-84.

  4. Instituto Mexicano del Seguro Social, H. C. Analisis estadistico del año 2012 de los padecimientos dermatologicos. 2013:L-30 y L70.

  5. Campalani E., and Barker, J.N.W.N The clinical genetics of psoriasis. Current Genomics.2005;6.1:51-60.

  6. Chouela, E.N. Epidemiología y genética de la psoriasis. Dermatol Argent.2011:17.3;236-239.

  7. Henseler, T. and Christophers, E. Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris. J Am Acad Dermatol.1985:13.3;450-456.

  8. González, Cesar, et al. Caracterización epidemiológica de la psoriasis en el Hospital Militar Central. Rev Asoc Col Dermatol.2008: 17;11-7.

  9. Arango, FA. Franco, MF. and Hoyos, AM. Psoriasis: conceptos actuales en el tratamiento sistémico. Parte 2. Medicamentos biológicos y no tradicionales. Rev Asoc Colomb Dermatol. 2011:45-54.

  10. Murphy, G., and K. Reich. In touch with psoriasis: topical treatments and current guidelines. Journal of the European Academy of Dermatology and Venereology. 2011;25.s4:3-8.

  11. Grau Serrano, P. and Mascaró Galy, JM. Metotrexato: actualización en el tratamiento de la psoriasis. Piel. 2006;21.7:358-363.

  12. Ryan, C., et al. Clinical and genetic predictors of response to narrowband ultraviolet B for the treatment of chronic plaque psoriasis. British Journal of Dermatology. 2010;163.5:1056-1063.

  13. Amir-Houshang, E. et al. Comparison of topical 8-methoxypsoralen and narrowband ultraviolet B with narrowband ultraviolet B alone in treatment-resistant sites in plaque-type psoriasis: a placebo-controlled study. Photodermatology, photoimmunology & photomedicine. 2011; 27.6: 294-296.

  14. Emerit, I. et al. Clastogenic Plasma Factors in Psoriasis— Comparison of Phototherapy and Anti–TNF-α Treatments. Photochemistry and photobiology. 2011; 87.6:1427-1432.

  15. Kleinpenning, M. M., et al. Efficacy of blue light vs. red light in the treatment of psoriasis: a double-blind, randomized comparative study. Journal of the European Academy of Dermatology and Venereology. 2012;26.2:219-225.

  16. Feldman, S. et al. Efficacy and Safety of Calcipotriene 0.005% Foam for the Treatment of Plaque-Type Psoriasis. American journal of clinical dermatology. 2012;13.4:261-271.

  17. Queille-Roussel, C. et al. Comparison of the antipsoriatic effect and tolerability of calcipotriol-containing products in the treatment of psoriasis vulgaris using a modified psoriasis plaque test. Clinical drug investigation. 2012:32.9:613-619.

  18. Maza, A. et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. 2011; 25.s2:19-27.

  19. Sánchez, Mikel. El plasma rico en plaquetas: ¿Una moda o una realidad? Archivos de medicina del deporte. 2010:252-254.

  20. Santa Coloma, E. Rolon, A. and Khoury, A. La actualidad del plasma rico en plaquetas en traumatología del deporte. Rev. Asoc. Argent. Traumatol. Deporte. 2011:18.1;30-43.

  21. Schön MP. Boehncke WH. Psoriasis. N Engl J Med. 2005:352:1899-1912.

  22. Kormeili, T., N. J. Lowe, and P. S. Yamauchi. Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; US experiences. British Journal of Dermatology. 2004:151.1;3-15

  23. Joshi, Rajiv. Immunopathogenesis of psoriasis. Indian Journal of Dermatology, Venereology, and Leprology. 2004:70.1;10.

  24. Winterfield, L. S., et al. Psoriasis treatment: current and emerging directed therapies. Annals of the rheumatic diseases. 2005:64.2;87-90.

  25. Weinberg, Jeffrey M., et al. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept. Journal of drugs in dermatology. 2004: 4.5;544-555.

  26. Ellis, Charles N., and Gerald G. Krueger. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. New England Journal of Medicine. 2001:345.4;248-255. 26. Dogra, Alka, and Silonie Sachdeva. Biologic therapy in psoriasis. Indian Journal of Dermatology, Venereology, and Leprology. 2006: 72.4;256-265.

  27. Menter, Alan, and Christopher EM Griffiths. Current and future management of psoriasis. The Lancet. 2007:370.9583;272-284.

  28. Tang, Min Moon, et al. Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study. International journal of dermatology. 2013: 52.3;314-322.




2020     |     www.medigraphic.com